RheoGene Inc. to Participate in CNS Focus Session at Eighth Annual Biotechnology Industry Organization (BIO) CEO and Investor Conference

RheoGene, Inc., a preclinical stage biotechnology company using its RheoSwitch® Therapeutic System and DirectIt™ Recombinase platform technologies to develop novel cell- and gene-based therapeutics for cancer and CNS disorders, today announced that RheoGene President and CEO Thomas Tillett will participate as a panelist in the Focus Session “CNS Disorders: Alzheimer's and Parkinson's -- What is on the Horizon?” at the Eighth Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City on Wednesday, February 15, 2006 at 8:30 pm EST in the in the East Foyer.

Norristown, PA (PRWEB) February 13, 2006 -- RheoGene, Inc., a preclinical stage biotechnology company using its RheoSwitch® Therapeutic System and DirectIt™ Recombinase platform technologies to develop novel cell- and gene-based therapeutics for cancer and CNS disorders, today announced that RheoGene President and CEO Thomas Tillett will participate as a panelist in the Focus Session “CNS Disorders: Alzheimer's and Parkinson's -- What is on the Horizon?” at the Eighth Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City on Wednesday, February 15, 2006 at 8:30 pm EST in the in the East Foyer.

Panelists will discuss novel approaches to the treatment of Alzheimer’s and Parkinson’s diseases, for which no standard cures are yet available. Mr. Tillett will discuss RheoGene’s work on the development of a gene therapy vector system with a regulatable “on switch” to treat Parkinson’s disease, a program that is supported by a $4.2M LEAPS award from the Michael J. Fox Foundation. While Parkinson’s disease is the first application, the work will have broad applicability to the safety and efficacy of gene therapies for many other diseases as well, and for their accelerated advancement into the clinic.

A live webcast of this focus session will be can be accessed on the BIO CEO Conference website at http://ceo.bio.org/opencms/ceo/2006/index.jsp.

About RheoGene Inc.

RheoGene is dedicated to unlocking the power of cell and gene therapy™. RheoGene’s proprietary RheoSwitch® Therapeutic System (RTS) and DirectIt™ recombinase platforms are the keys to safe, targeted and regulated cell and gene therapies that deliver the right dose -- to the right place -- at the right time. RheoGene also provides customized RheoSwitch® inducible gene expression and AttSite™ recombinase products for pharmaceutical discovery and development and biotherapeutics production. RheoGene Inc. is a wholly owned affiliate of the University of Pittsburgh Medical Center with operations in Norristown, PA and Pittsburgh, PA.

For more information, visit www.rheogene.com.

###